CordovaCann (LVRLF) Liabilities and Shareholders Equity (2012 - 2025)
CordovaCann (LVRLF) recorded quarterly Liabilities and Shareholders Equity of $4.6 million in Q2 2025, down 33.81% quarter-over-quarter from $7.0 million in Q2 2024, and down 33.81% on a YoY basis from $7.0 million in Q2 2024.
CordovaCann (LVRLF) Liabilities and Shareholders Equity (2012 - 2025) Analysis & Trends
CordovaCann's Liabilities and Shareholders Equity history runs 14 years deep, the most recent figure standing at $4.6 million for Q2 2025.
- In Q2 2025, Liabilities and Shareholders Equity fell 33.81% year-over-year to $4.6 million; the TTM figure through Jun 2025 stood at $32.4 million (down 22.55% YoY), while the FY2025 annual figure was $4.6 million, down 34.89% from the prior year.
- Liabilities and Shareholders Equity was $4.6 million for Q2 2025 at CordovaCann, down from $7.0 million in the prior quarter.
- In the past five years, Liabilities and Shareholders Equity ranged from a high of $14.1 million in Q2 2021 to a low of $4.6 million in Q2 2025.
- Historically, Liabilities and Shareholders Equity has averaged $9.3 million across 5 years, with a median of $7.6 million in 2023.
- The sharpest annual moves came in 2021 and 2023: Liabilities and Shareholders Equity soared 32.61% in 2021, then plunged 41.84% in 2023.
- A 5-year view of Liabilities and Shareholders Equity shows it stood at $14.1 million in 2021, then declined by 6.51% to $13.1 million in 2022, then slumped by 41.84% to $7.6 million in 2023, then fell by 8.58% to $7.0 million in 2024, then sank by 33.81% to $4.6 million in 2025.
- The last three Liabilities and Shareholders Equity figures came in at $4.6 million (Q2 2025), $7.0 million (Q2 2024), and $7.6 million (Q2 2023), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.97 Bn | 36.23 Bn | 1.97 Bn | 40.04 Bn |
| 2 | Zoetis | 33.59 Bn | 31.65 Bn | 1.62 Bn | 15.15 Bn |
| 3 | United Therapeutics | 23.75 Bn | 21.60 Bn | 648.10 Mn | 6.71 Bn |
| 4 | Neurocrine Biosciences | 16.10 Bn | 14.78 Bn | 800.70 Mn | 4.91 Bn |
| 5 | Aurora Cannabis | 15.56 Bn | 15.47 Bn | 21.72 Mn | - |
| 6 | Elanco Animal Health | 12.04 Bn | 11.61 Bn | 785.00 Mn | 13.22 Bn |
| 7 | Alkermes | 7.36 Bn | 6.84 Bn | -116.06 Mn | 4.26 Bn |
| 8 | Lantheus Holdings | 6.74 Bn | 6.24 Bn | 230.92 Mn | 2.35 Bn |
| 9 | Liquidia | 6.27 Bn | 6.04 Bn | 121.79 Mn | 401.53 Mn |
| 10 | CordovaCann | - | - | - | 4.62 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 4.62 Mn |
| Jun 30, 2024 | 6.98 Mn |
| Jun 30, 2023 | 7.64 Mn |
| Jun 30, 2022 | 13.14 Mn |
| Jun 30, 2021 | 14.05 Mn |
| Jun 30, 2020 | 10.60 Mn |
| Mar 31, 2020 | 3.72 Mn |
| Dec 31, 2019 | 3.45 Mn |
| Sep 30, 2019 | 3.51 Mn |
| Jun 30, 2019 | 3.47 Mn |
| Mar 31, 2019 | 2.55 Mn |
| Dec 31, 2018 | 2.59 Mn |
| Sep 30, 2018 | 3.02 Mn |
| Jun 30, 2018 | 3.78 Mn |
| Mar 31, 2018 | 720,888.23 |
| Dec 31, 2017 | 164,173.47 |
| Sep 30, 2017 | 2,154.59 |
| Jun 30, 2017 | 5,024.55 |
| Mar 31, 2017 | 5,848.85 |
| Dec 31, 2016 | 8,665.72 |